DK0607278T3 - Method of Intestinal Absorption Enhancement - Google Patents

Method of Intestinal Absorption Enhancement

Info

Publication number
DK0607278T3
DK0607278T3 DK92921577T DK92921577T DK0607278T3 DK 0607278 T3 DK0607278 T3 DK 0607278T3 DK 92921577 T DK92921577 T DK 92921577T DK 92921577 T DK92921577 T DK 92921577T DK 0607278 T3 DK0607278 T3 DK 0607278T3
Authority
DK
Denmark
Prior art keywords
intestinal absorption
absorption enhancement
enhancing
mammal
production
Prior art date
Application number
DK92921577T
Other languages
Danish (da)
Inventor
Douglas Wilmore
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK0607278T3 publication Critical patent/DK0607278T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention provides a method for enhancing the gut absorption in a mammal. Specifically, gut absorption in a mammal can be enhanced by the administration of glutamine, or glutamine equivalent, in combination with one or more agents, said agents selected from the group consisting of growth hormone (GH), an agent capable of enhancing endogenous GH production, insulin like growth factor 1 (IGF-1), or an agent capable of enhancing endogenous IGF-1 production.
DK92921577T 1991-10-07 1992-10-07 Method of Intestinal Absorption Enhancement DK0607278T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77141591A 1991-10-07 1991-10-07
PCT/US1992/008445 WO1993006839A1 (en) 1991-10-07 1992-10-07 Method for enhancing gut absorption

Publications (1)

Publication Number Publication Date
DK0607278T3 true DK0607278T3 (en) 2002-06-17

Family

ID=25091736

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92921577T DK0607278T3 (en) 1991-10-07 1992-10-07 Method of Intestinal Absorption Enhancement

Country Status (11)

Country Link
US (1) US5288703A (en)
EP (1) EP0607278B1 (en)
JP (1) JP3614427B2 (en)
AT (1) ATE216253T1 (en)
AU (1) AU661242B2 (en)
CA (1) CA2120626C (en)
DE (1) DE69232561T2 (en)
DK (1) DK0607278T3 (en)
ES (1) ES2174838T3 (en)
IL (1) IL103383A0 (en)
WO (1) WO1993006839A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0776213A1 (en) * 1994-09-21 1997-06-04 Pharmacia & Upjohn Aktiebolag Method of treating hypertension in pregnant mammals
GB9609993D0 (en) * 1996-05-14 1996-07-17 Norbrook Lab Ltd Oral rehydration product
GB2329336B (en) * 1996-05-14 1999-11-10 Norbrook Lab Ltd Oral rehydration product comprising glutamine
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
US5981590A (en) * 1997-03-17 1999-11-09 Probiotix, Inc. Oral glutamine in the prevention of neonatal necrotizing enterocolitis and other gastrointestinal mucosal damage
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
JP2004536834A (en) * 2001-07-06 2004-12-09 オークランド ユニサーヴィシズ リミテッド Hypertension treatment
US20030099722A1 (en) * 2001-10-09 2003-05-29 Baxter Jeffrey H. Methods and compositions for providing glutamine
AU2003250250B2 (en) 2002-06-19 2008-02-14 Intrexon Actobiotics Nv Methods and means to promote gut absorption
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
CA2538904C (en) * 2003-09-12 2013-03-12 Paul Wischmeyer Glutamine for use in treating injury
PL370937A1 (en) * 2004-10-29 2006-05-02 Sgp & Sons Ab Nutritional and/or pharmaceutical preparation for use in the prevention and treatment for the deficiency in absorption of microelements from the alimentary canal as well as application of pharmaceutical preparation stimulating absorption of microelements
EP1957100B1 (en) 2005-11-29 2016-07-13 Intrexon Actobiotics NV Induction of mucosal tolerance to antigens
EP2774621B1 (en) 2007-01-25 2018-01-24 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
JPWO2018079573A1 (en) * 2016-10-26 2019-09-19 味の素株式会社 Composition for improving absorption reduction in digestive tract and composition for promoting absorption in digestive tract

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001038A1 (en) * 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
US4857555A (en) * 1985-09-12 1989-08-15 Brigham & Women's Hospital Method of treating catabolic dysfunction
US4863901A (en) * 1986-01-09 1989-09-05 Brigham & Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5164370A (en) * 1987-12-24 1992-11-17 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US5122512A (en) * 1988-09-12 1992-06-16 Pitman-Moore, Inc. Swine growth promoting composition
SE9002732D0 (en) * 1990-08-24 1990-08-24 Kabivitrum Ab PRODUCT CONTAINING GROWTH FACTOR

Also Published As

Publication number Publication date
JP3614427B2 (en) 2005-01-26
EP0607278B1 (en) 2002-04-17
DE69232561T2 (en) 2002-11-28
ES2174838T3 (en) 2002-11-16
EP0607278A1 (en) 1994-07-27
US5288703A (en) 1994-02-22
DE69232561D1 (en) 2002-05-23
WO1993006839A1 (en) 1993-04-15
EP0607278A4 (en) 1995-03-29
IL103383A0 (en) 1993-03-15
AU2790692A (en) 1993-05-03
CA2120626C (en) 2009-10-06
CA2120626A1 (en) 1993-04-15
JPH07501796A (en) 1995-02-23
AU661242B2 (en) 1995-07-13
ATE216253T1 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
DK0607278T3 (en) Method of Intestinal Absorption Enhancement
EA200300026A1 (en) GLUKAGONOPODODODNOGNY PEPTIDA-1 ANALOGUES
ATE314393T1 (en) DELAYED RELEASE OF INSULINOTROPINE (GLP-1)
CO4970787A1 (en) INSOLUBLE COMPOSITIONS OF INSULIN AND INSULIN DERIVATIVES THAT CONTROL BLOOD GLUCOSE
DE69334035D1 (en) PROCEDURE FOR PREVENTING NMDA RECEPTOR MEDIATED NEURONAL DAMAGE
ATE254095T1 (en) SELECTIVE ANALOGUE OF THYROID HORMONES
DK588487D0 (en) IMPROVED METAL CONTAINING PHARMACEUTICAL AGENTS
MXPA04001525A (en) Glucagon-like peptide-1 analogs.
SE9003665D0 (en) MORPHINE PRODRUGS
EA200000748A1 (en) METHOD OF INTRODUCTION OF MONOMERIAL INSULIN ANALOGUES
DK0424028T3 (en) S (+) - ibuprofen-L-amino acid and S (+) - ibuprofen-D-amino acid as an improved analgesic with accelerated onset
NZ236614A (en) Therapeutic composition containing corticosteroid and igf-i, the igf-i reducing or preventing the adverse effects of the corticosteroid
DE69004107D1 (en) Flux composition.
ES2108122T3 (en) COMPOSITION BASED ON AMYLINE OR AN AMYLINE ANALOG CONTAINING OPTIONALLY INSULIN, FOR THE TREATMENT OF ANOREXIA AND ASSOCIATED PATHOLOGIES.
JPS5251755A (en) Agents for treating excreta
ATE110961T1 (en) TREATMENT OF VENTILATION DEPENDENCE WITH GROWTH HORMONE.
DK0506716T3 (en) Method of treating thrombocytopenia and pharmaceutical compositions suitable for this purpose
DE69126180D1 (en) TREATMENT OF POLYCYSTIC OVARIAN DISEASE
DK0586592T3 (en) Insulin and amylin-containing composition for the treatment of insulin-deficient mammals
DE69112642D1 (en) LYOPHILIZED AMINOCARBONIC ACID COMPOSITIONS WITH GLUTAMINE.
Baxter The golden years
KR920001467U (en) Tip for combined solution injector (SIP)
JPS549255A (en) Tricyclo(4.3.1.12,5)undecane-1-carboxylic acid and process for its preparation
UA88862C2 (en) Glucagon-like peptide-1 analogs
JPS52143501A (en) Molten metal injection pump